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ABSTRACT 
Clinical outcome for patients with primary biliary cholangitis (PBC) is dictated by 
development of cirrhosis, portal hypertension and its associated complications; 
including for some, a predisposition toward hepatocellular carcinoma. However rates 
of clinical progression vary, and accurately identifying disease course is of critical 
importance to patients, clinicians, as well as industry, who are committed to 
developing new effective and life-prolonging therapy as well as treating symptoms 
that appear disproportionate to underlying disease severity.  
 
Patients seek reassurance and guidance as to their own prognosis, and clinicians wish 
to confidently recognise those at highest risk of poor outcomes as equally as they 
strive to reassure individuals with a more favourable disease trajectory. International 
registries have facilitated a much greater knowledge of disease incidence and 
heterogeneity of presenting phenotypes. In so doing they highlight the opportunity to 
provide a more individualized estimate of the clinical course that patients experience, 
and have led to a renewed approach to risk stratification; both in terms of ‘hard 
outcomes’ and also disease-associated complications in PBC specifically. 
 
Keywords: 
Primary biliary cholangitis; hepatic complications; decompensation; hepatocellular 
carcinoma; disease progression; APRI; stratification 
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Introduction 
Whilst today we recognise more clearly the heterogeneous rates of disease 
progression that patients with primary biliary cholangitis (PBC) experience, this was 
less evident in older studies; in part a reflection of centre and referral bias, as well as 
the absence of very large cohort data to capture the broader spectrum of disease, both 
before and after intervention. This means some caution needs to be exercised when 
reviewing outcome data from earlier studies, as our understanding of PBC no longer 
considers the disease a single homogeneous process.  
 
Within these constraints, historic population-based data from the UK illustrate that the 
average survival of untreated patients with ‘classical PBC’ is approximately 9-10 
years from presentation, with ~25% developing chronic liver failure during this time 
(1). In the absence of effective therapy, the median time to develop extensive liver 
fibrosis was approximately 2 years, with a probability of remaining in early stage 
disease of 29% over 4 years (2-4). An early prospective study (n=236) identified that 
more than 50% of patients with stage 1-III PBC developed histologically proven 
cirrhosis within 4 years (5). Reciprocally, studies from the Mayo Clinic indicate that 
progression to cirrhosis after a follow-up period of 6 years was evident in 49% of all 
patients from the point of diagnosis (6).  
 
However, fuller understanding of disease has evolved following the advent of anti-
mitochondrial antibody (AMA) testing; reactivity of which in the presence of 
cholestasis facilitates detection at an earlier stage, often without need for liver biopsy 
(7-9). In a multicentre study conducted by the Global PBC Group (n=4805), not only 
was the mean age at PBC diagnosis seen to increase over time (from 47+10 years in 
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the 1970s to 57+12 years from 2010 onwards), but the proportion of patients having 
features of more aggressive presenting biochemical disease also changed 
significantly, with only 51% and 30% of patients diagnosed in the 1970s expressing a 
normal serum bilirubin or serum alkaline phosphatase (ALP) below twice the upper 
limit of normal (ULN), respectively, vs. 78% and 63% for patients diagnosed after 
2010 (10). Notably, of the group with available liver histology (n=2217), 60% were 
identified as having early disease (stage I-II) when diagnosed pre-1990, rising to 77% 
for patients presenting after 2010.  
 
The latter finding may explain the observed improvement in 10-year transplant free 
survival rates between aforementioned time points (48% vs. 80%) (10), at least in 
part. Application of the original histological classification systems proposed by 
Ludwig (11), Rubin (12) and Scheuer (13) have been shown to stratify the risk of 
disease progression in patients with PBC, which is perhaps best highlighted by the 
study published by Corpechot in 2008 (14). Across a prospectively evaluated cohort 
of 292 patients, the investigators showed that stage III-IV liver fibrosis, or moderate–
severe interface hepatitis, purported a significantly increased risk of death or liver 
transplantation independently of liver biochemical values and UDCA treatment status 
(adjusted relative risk [RR] 1.5 and 1.9, respectively). However, the Toronto group 
report that significant ductopenia, defined as >50% bile duct loss at diagnosis, 
independently predicted histological fibrosis progression, and overrides the prognostic 
impact of interface hepatitis in the same biopsy specimens (15).  
 
The degree of intrahepatic bile duct loss is usually not severe enough to cause 
jaundice unless established cirrhosis is present; however, a subgroup of patients with 
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PBC suffer with severe cholestatic jaundice and profound ductopenia in the absence 
of significant cirrhosis or fibrosis (16). In this ‘premature ductopenic variant’ patients 
are plagued by severe pruritus, may have cholestatic jaundice and be malnourished 
due to fat malabsorption in the absence of hepatocellular failure or significant portal 
hypertension. This form may affect 5-10% of PBC patients and although the extent of 
fibrosis may be limited initially, development of cirrhosis seems to be inevitable and 
rapid. Patients are unresponsive to UDCA therapy, and due to the markedly decreased 
quality of life and adverse effect of chronic severe cholestasis this progressive disease 
evolves over the course of <5 years to a stage where liver transplantation should be 
considered, even in the absence of significant fibrosis.  
 
Many, more contemporary histological systems have been developed for studying 
PBC (17-19), with the aim of better characterising interface activity, ductopenia, 
chronic cholestasis and fibrotic indices (14-16, 20-22). However, as discussed, 
diagnosing PBC no longer requires liver biopsy; for disease identification is largely 
reliant on the biochemical context of presentation, in conjunction with positive 
serology (AMA; or anti-nuclear antibodies of the anti-sp100 or anti-gp210 class) (23). 
Whilst histology remains the ‘gold-standard’ for assessing the burden of inflammatory 
activity and fibrosis progression, the intrusiveness coupled with well-known sampling 
variability, disconcordant reporting in cholestatic disease, and non-routine 
applicability in clinical practice, has fostered the study of several non-invasive 
surrogates. The accuracy of vibration-controlled transient elastography (VCTE) in 
fibrosis staging has been demonstrated in several large PBC cohorts (24, 25), with 
prognostic capabilities independent of biochemical response evident in a single-centre 
retrospective experience of 150 patients (24). These studies are almost exclusively 
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conducted in UDCA-treated cohorts, and estimate that 50-55%, 20-21%, 14.5-17% 
and 8-14.5% of PBC patients have stage F0-F1, F2, F3 and F4 fibrosis respectively at 
diagnosis. The annual progression rate for F0-F3 fibrosis was 0.48 (±0.21) kPa, 
increasing to 4.06 (±0.72) kPa/year for those with stage F4 fibrosis. Perhaps most 
striking, a liver stiffness value >9.6 kPa (hazard ratio [HR]: 8.4), or an increase by 
>2.1 kPa/year (HR): 1.3) were identified as significant discriminatory thresholds for 
progression to hepatic decompensation events, liver transplantation or death (24).  
 
The fact that most patients are now diagnosed at an earlier stage of disease in an era 
where liver biopsy does not constitute routine standard of care effectively precludes 
the study of ‘hard’ endpoints (histological progression, liver transplantation, death) 
when testing new therapy. Such challenges have driven a wealth of investigation into 
potential surrogate markers and risk prediction models, which highlight the impact of 
data that is sufficiently powered through duration of follow-up, and by the number of 
clinical events captured. Elevated serum bilirubin is well established as a marker of 
poor clinical outcome, and incorporated into historical prognostic models such as the 
Mayo PBC risk score to predict short-term survival (<2 years) in patients with 
advanced liver disease (26, 27). A study from New York in the 1970s showed that 
individuals with PBC initially experience a stable period of disease during which 
bilirubin remains constant, although once they develop a rapid rise in serum values, 
this signified a late-phase of disease and death would inevitably follow (calculated 
survival time for bilirubin values >34µmol/L, >102µmol/L and 170µmol/L of 4 years, 
25 months and 17 months, respectively) (28).  
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A potentially more applicable surrogate early in the disease course is serum ALP. In 
the largest ever meta-analysis of individual patient data (n=4845), a near log-linear 
relationship was shown between ALP and subsequent risk of transplantation/death 
across several time points (29). This study demonstrated that ALP bestows prognostic 
information incremental to the predictive power of bilirubin and independent of 
follow-up time, presenting age, sex, disease stage, and treatment status (29). To this 
effect, several studies published between 2006-2014 illustrated strong associations 
between percentage reduction or absolute decreases/normalization in serum ALP over 
time (in isolation or combination with other biochemical covariates) and significantly 
improved clinical outcome (14, 15, 30, 31) (Figure 1). Although these ‘biochemical 
response criteria’ were originally derived from individual cohorts under UDCA 
therapy, they have subsequently been independently and externally validated at a 
multi-centre and international level inclusive of non-treated patients (20, 32, 33). 
These parameters form the benchmark for which treatment efficacy is gauged in PBC, 
as well as representing inclusion criteria for contemporary interventional studies of 
second-line therapy. It remains unclear, however, whether liver fibrosis stage (or its 
non-invasive assessment) confers additive predictive value. 
 
Clinical course in the era of ursodeoxycholic acid (Figure 2) 
Up until 2017, UDCA has been the only licensed medical therapy for PBC. The 
prospective, non-controlled pilot study reported by Poupon et al. in 1987 (n=15) was 
one of the first to demonstrate an improvement in serum liver biochemistry in PBC, 
with a mean reduction in serum ALP, alanine aminotransferase (ALT) and bilirubin 
values of 65%, 68% and 36% respectively of pre-treatment values following 2 years 
of UDCA treatment (dosage: 13-15 mg/kg/day) (34). Notably, for patients in whom 
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the drug had been stopped, a prompt rebound of serum biochemical values to pre-
treatment levels was observed. A two-year double-blind multi-centre randomised 
controlled trial (RCT) led by the same group soon followed (n=146 patients), and 
showed that the mean serum bilirubin, ALP and ALT values decreased by 9%, 56% 
and 52% respectively from baseline, versus an increase of 68%, increase of 6% and an 
increase of 2% in the UDCA- and placebo-treated groups, respectively (p<0.001 for 
all comparisons) (35) .  
 
The impact of UDCA treatment on serum liver biochemistry has been supported 
through a further wealth of clinical trial activity across North America and Europe. 
However, determining the impact of therapy on histological disease progression has 
proven more controversial given that liver biopsy is not performed routinely, 
particularly for patients in whom advanced disease is already evident. Nevertheless, 
paired liver biopsies from a proportion of the trial participants comprising the 
Canadian, French and Spanish studies (63%, 65%, and 44% of the original study 
cohorts, respectively) illustrate a variable improvement in scorings of bile duct 
paucity, ductular proliferation, leucocytic infiltrate, piecemeal necrosis, lobular 
inflammation, parenchymal necrosis and histological stage of disease in the UDCA 
treated-groups, and in a greater number of patients compared to placebo (35-37). The 
Mayo clinic data lent further support to this observation, wherein UDCA treatment 
significantly delayed histological progression to cirrhosis over 6.6±0.4 years (13% vs. 
49% in UDCA-treated vs placebo-treated patients respectively, p<0.009) (6). 
Applying a Markov model to 103 patients from the French cohort further 
demonstrated a 5-fold lower progression rate from early stage disease to extensive 
liver fibrosis or cirrhosis (7% per year under UDCA vs. 34% under placebo, 
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p<0.002), with a 4-year probability of remaining in early stage disease of 76% vs. 
29%, respectively (4). However, no significant changes in the degree of inflammatory 
activity or histological stage was observed in a prospective randomised trial of 61 
patients from the Mayo clinic (38); and in a combined analysis of the 4 RCTs from 
Canada, France, Spain and the United States (n=367 overall; 200 of which were 
UDCA-treated), significant differences histologically were restricted to improvements 
in periportal necroinflammatory lesions and ductular proliferation, and only in the 177 
patients having a baseline histological disease stage of I-II (39).  
 
A protective effect of UDCA on the development of oesophageal varices has also 
been addressed prospectively, and in a study of 180 patients the 4-year probability 
was significantly lower in treated versus untreated individuals (16% vs. 58%; 
p<0.001) (40). Moreover, in an extension of the French clinical trial wherein both 
treatment arms subsequently received UDCA for a further two years, the incidence of 
hepatic decompensation, doubling of bilirubin, liver transplantation and death was 
significantly lower in patients treated with UDCA from the outset versus those 
originally randomised to placebo (9/72 vs. 20/73; RR: 0.28, p<0.002) (41). A meta-
analysis of three RCTs (Mayo Clinic, USA; Canadian multi-centre; French multi-
centre) provides further evidence of improved transplant-free survival in UDCA-
treated patients (RR: 1.9, p<0.001) (42).  
 
Conversely, the multi-centre trial by Combes et al. (n=150; UDCA dosage of 10-12 
mg/kg/day) yielded more sobering results, with no significant difference in the 
incidence of hepatic decompensation, liver transplantation and mortality between 
UDCA- and placebo-treated groups over two years (56% vs. 69%, p=0.098) (43). The 
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RCTs from Spain (n=192; UDCA dosage of 14-16 mg/kg/day), Sweden (n=116; 500 
mg/day), and Greece (n=86; 12-15 mg/kg/day) raised further questions over the 
impact on long-term clinical outcomes (37, 44, 45); wherein despite improvements in 
serum biochemistry (all 4 studies) and liver histology (Spanish study only), the 
transplant-free survival between UDCA- and placebo-treated patients was not 
significantly different. To this effect, several meta-analyses debate the prognostic 
merit of UDCA therapy in PBC (46). However, when interpreting such data, note 
must be taken of the number of patients enrolled, whether evaluation was of 
individual studies or of individual patient data, the baseline stage of disease in which 
UDCA was commenced, and the dosage of medication used. In an RCT of 155 
patients, which gauged treatment effect by the magnitude of improvement in serum 
liver biochemistry values over two years, a dose of 13-15 mg/kg/day was shown to be 
superior to 5-7 mg/kg/day, and similar to 23-25 mg/kg/day (47).  
 
Meta-analysis of the early clinical trials confined to those using an appropriate UDCA 
dose and with sufficient follow-up (at least 2 years; n=522 under UDCA treatment 
and n=516 who received placebo) has validated the improvement in liver biochemical 
values that were observed in the individual studies, although histologic evidence of 
disease progression was no different between groups (48). A total of 160 patients who 
were treated with UDCA and 186 control subjects died or underwent liver 
transplantation. This difference was significant in a fixed-effect model, although both 
suggested a clinically important treatment effect that was not significant because of an 
insufficient number of patients (48).  
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Nevertheless, definitive evidence of therapeutic efficacy was provided in 2014, via a 
multi-centre, individual patient data meta-analysis conducted by the Global PBC 
Study Group (n=4,845) (29). This landmark study confirmed significantly improved 
liver transplant free survival for treated versus untreated individuals (at 5 years, 10 
years and 15 years: 90%, 78%, and 66% for UDCA-treated patients, respectively; vs. 
79%, 59%, and 32% in the non-treated group, respectively; p<0.001 for all 
comparisons) (29). Pooled survival indices in the PBC population nevertheless remain 
lower than age- and sex-matched controls despite therapy, fuelling intense 
investigation into the factors defining UDCA treatment efficacy.  
 
Linking biochemical surrogates to therapeutic efficacy  
It has been suggested that any impact on transplant-free survival in UDCA vs. 
placebo-treated groups is attenuated following adjustment of baseline disease stage 
(49). However a combined analysis of trials from the Mayo clinic, Canada and 
France, suggested that the 4-year transplant-free survival rate is significantly 
improved even for patients classified as medium-risk (starting bilirubin 1.4-3.5 
mg/dL), high risk (bilirubin >3.5 mg/dL) or with stage IV histological disease (42). 
The strong association between serum biochemistry and clinical response has been 
extensively studied given that the magnitude of biochemical change is not necessarily 
equal from patient to patient. Indeed, biochemical response criteria (Figure 1) provide 
good evidence to show that percentage reduction or absolute decreases/normalisation 
in serum bilirubin and ALP whilst on UDCA therapy, together with other biochemical 
covariates, are strongly predictive of prognosis (50).  
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The original UDCA response models continue to be refined across different patient 
populations (14, 15, 31, 51), and all currently proposed criteria highlight that an 
absence of biochemical improvement has clear prognostic implications. 
Approximately 60-70% of all patients with PBC successfully attain pre-defined 
biochemical thresholds within 6-24 months after UDCA-treatment, which are strongly 
associated with improved clinical outcomes, and a transplant-free survival akin to that 
of an age- and sex-matched population. By contrast, so-called ‘biochemical non-
responders’ represent a high-risk group for disease progression and need for liver 
transplantation.  
 
Although biochemical response criteria were originally derived from single-centre 
reports, all have been independently, externally and robustly validated at a global 
level (20, 32, 52), representing the highest level of evidence for risk prediction and 
stratification into PBC clinical trials (50). Whilst a small proportion with early-stage 
disease meet criteria free of therapy (53), this represents an understudied population 
and presently it is not yet possible to identify patients with a good prognosis 
regardless of intervention. Thus, UDCA is recommended as the first line treatment in 
all patients with PBC from the point of diagnosis (7). 
 
Biochemical response criteria continue to be refined, and newer more sophisticated 
algorithms have been developed incorporating conventional parameters indicative of 
biochemical response and disease severity. By interrogating large, international multi-
centre cohorts to predict transplant free survival, application of the AST/platelet ratio 
index (APRI), UK-PBC and GLOBE scores, are all shown to outperform prior 
biochemical response criteria for the prediction of death/liver transplantation (32, 52, 
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54). For instance, a GLOBE score of >0.30, which applied to 40% of UDCA-treated 
patients (n= 2488) was associated with a significant reduction in survival compared to 
age- sex- and calendar time matched population (32), improving the net classification 
of patients in to low- and high- risk groups by 10% (7).  
 
Therapeutic options for UDCA non-responders 
Non-response to UDCA is the current pre-requisite for consideration of second line 
treatment, although patients with an elevated APRI or fibrosis score according to 
VCTE represent additional high-risk groups (50). In 2016, obeticholic acid (OCA) 
gained approval as second-line therapy for PBC, following on from the successful 
results of respective clinical trials (55-57). The POISE phase III study recruited 
patients with PBC exhibiting a persistent elevation in serum ALP (prior biochemical 
non-response according to the modified Toronto criterion (15), and/or an elevated 
bilirubin; or reported intolerance to UDCA. The study involved three treatment arms: 
OCA at a dose of either 5 mg/day, 5 mg/day titrated up to 10 mg/day, and placebo. 
The primary endpoint during the 12-month double-blind period was attainment of 
both an ALP value <1.67 × ULN (with a ≥15% reduction from baseline) and a normal 
serum bilirubin. In an intention-to-treat analysis, the primary endpoint was met in 
10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-
titrated OCA groups, respectively (p<0.0001 for both). Moreover, the mean decrease 
in serum ALP from baseline was 39% and 33% in the 10 mg and titrated OCA-
groups, respectively, versus 5% for patients in receipt of placebo (p<0.0001 for both). 
Both OCA groups met pre-defined secondary endpoints including a reduction in 
serum AST and total serum bilirubin (both OCA groups p<0.001 vs. placebo).  
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OCA monotherapy (10 mg and 50 mg/day) has also shown statistically significant 
reductions in mean serum ALP values from baseline vs. placebo (-53.9% and -37.2% 
vs. 0.8%; p<0.0001) (57); and longer-term efficacy is currently being studied across 
prospective clinical outcome studies in PBC. This is of particular importance given 
the relative infrequency of PBC globally (9), and hence the limited number of patients 
studied thus far. Up till now, enrolment into clinical trials has been restricted to 
individuals demonstrating persistent elevations in serum ALP, with therapeutic 
efficacy gauged through percentage change or absolute decline. It is plausible 
therefore, that the beneficial effect of OCA will be restricted to patients failing to 
achieve biochemical response based on ALP criteria. However, there is no currently 
available data regarding therapeutic efficacy stratified according to the magnitude of 
serum ALP elevations at point of trial inclusion. Assessment of further surrogates of 
clinical outcome, including for instance APRI and liver stiffness measurements 
derived via transient elastography, would be of additional clinical benefit in this 
regard. 
 
The ability of fibric acid derivates to exert anti-cholestatic effects (via activation of 
peroxisome proliferator-activated receptors [PPAR]) has received a wealth of 
attention as adjunctive therapy to UDCA, although currently represents an unlicensed 
intervention for PBC. A pooled complete biochemical response rate using fenofibrate 
+UDCA combination therapy is evident in 69% of patients, according to systematic 
review and meta-analysis by Grigorian et al. (58); and in a retrospective study 
conducted by the Toronto group (59) improvements in short-term liver 
decompensation-free and transplant-free survival, independently of liver biochemical 
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changes, were seen across a cohort of 120 prior UDCA non-responders (log rank 
p<0.001) (59).  
 
Improvements in liver biochemistry are also evident using bezafibrate. In a non-
blinded prospective randomised-controlled study (n=27; 100-120 months of 
treatment), serum ALP values were significantly lowered following 
UDCA+bezafibrate combination therapy (mean 290 IU/L+0.91) vs. UDCA alone 
(mean 461 IU/L+1.42; p<0.05), and associated with a trend toward improved overall 
survival (log rank p=0.057) (60). The Barcelona open-label study (n=28) also 
provides evidence of a significant improvement in itch severity, wherein all 12 
patients who reported itch prior to starting bezafibrate treatment achieved complete or 
partial symptom resolution (61). Moreover, 20 and 24 UDCA non-responders attained 
a serum ALP reduction >40% within 6 and 12 months, respectively, with combination 
therapy (61). In an extension of these findings, n=26/48 UDCA-treated patients 
having an ALP persistently elevated >1.5xULN had normalised serum values over a 
median of 38 months, with partial or complete symptom resolution in all participants 
(62). 
 
Despite improving surrogate markers of long-term prognosis, the depth of evidence 
supporting bezafibrate and fenofibrate in PBC has, up till now, remained limited to 
mostly groups of patients outside of clinical trial settings or with limited duration of 
follow-up. Moreover, the biochemical improvements associated with fibric acid 
derivatives have not been shown to sufficiently alter long-term probability of liver-
related death or need for transplantation when stratified according to the UK-PBC risk 
score (54, 63), and may be counterbalanced by a negative impact on renal function 
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(60). In light of these limitations, a double-blind RCT evaluating bezafibrate in 
UDCA non-responders (Paris-II criteria; n=100) has recently completed. The primary 
endpoint was normalisation of all liver biochemical parameters and prothrombin time 
following 24 months of treatment, and met in 15 patients (30%) within the 
bezafibrate+UDCA combination arm vs. 0% with placebo+UDCA alone (64). 
Notably, ~70% of patients met biochemical response criteria in the bezafibrate 
treatment arm in addition to a 10% reduction of liver stiffness as measured by VCTE, 
compared to only 10% and +14% with placebo (p<0.001 and <0.01, respectively). 
Formal reporting of study findings is eagerly anticipated. 
 
Very recently, the results of a clinical trial selectively targeting PPAR-δ have been 
published (65). In a multi-centre and international phase II double-blind placebo-
controlled RCT, UDCA non-responders (Toronto criterion) received either 
Seladelapar in one of two doses, 50 mg/d or 200 mg/d, or placebo in a 1:1:1 study 
design (n=13, 10 and 12, respectively). Mean changes from baseline in serum ALP 
were; -2% in the placebo group, vs. -53% and -63% in the Seladelpar 50 mg and 200 
mg groups, respectively (p<0.0001 for both groups vs. placebo). Unfortunately, 3 
patients developed grade III elevations in serum aminotransferases (reversible on 
treatment cessation) and the study was prematurely terminated. Nevertheless, all five 
participants who received Seladelpar for the full 12 weeks normalised ALP values by 
the end of treatment. 
 
Emerging insights into genetic risks and biological pathways have led to additional 
interest in therapies aimed at modulating bile acid physiology and targeting specific 
immune responses (Figure 3). Whilst appropriate risk stratifiers and surrogate 
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endpoints of treatment efficacy now exist (50), early disappointing results with 
immunomodulation and molecular targeted therapies highlight critical difficulties in 
translating basic immunological insights into routine clinical practice (66). As our 
understanding of disease pathogenesis continues to evolve, it is hoped that a stepwise 
understanding of disease progression may permit more ‘time course initiated’ 
interventions, from the incipient stages of immune-intolerance, through to 
parenchymal remodelling and anti-fibrotic therapy in patients with established 
cirrhosis (67). A more detailed discussion of therapeutic alternatives in PBC is 
beyond the scope of this review, and will be covered elsewhere in this issue (68). 
 
Complications (tentatively) linked to severity of liver disease 
Portal hypertensive disease 
Approximately 35% of patients have features of portal hypertension at presentation 
defined as a porto-hepatic gradient (PHG) >6 mmHg, Table 1 (69). Notably, a 
significant difference in transplant-free survival is recognised when stratifying 
individuals according to low (<6 mmHg; n=86), intermediate (6–12 mmHg; n=20) 
and high (>12 mmHg; n=26) PHG values. There is further evidence that a reduction 
in hepatic veno-portal gradient (HVPG) whilst on UDCA-treatment associates with 
improved clinical outcome, stratifying through a 20% gradient-decline over 2 years 
(69). Of note, elevated AST values at baseline and 1 year after onset of UDCA were 
associated with an increased risk of death and liver transplantation in the same study 
(14, 52), and normalisation within 2 years of UDCA treatment was the only 
laboratory parameter significantly related to improved overall survival. 
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The rate at which portal hypertension develops throughout the clinical course of a 
PBC population is less well studied, given that regular and invasive pressure 
assessments do not form part of standard clinical practice. The prognostic capabilities 
of non-invasive surrogates such as APRI have thus been ascertained in PBC, given 
ability to infer portal hypertension non-invasively, and also the presence of liver 
fibrosis. Indeed, APRI has now been validated as an independent predictor of 
transplant-free survival across several international cohorts (52, 70, 71), and when 
applied at 1 year following UDCA therapy is able to identify the sub-group of PBC 
patients at risk of liver disease progression and earlier mortality, independently and 
additively to biochemical response criteria (Figure 1). 
 
Whilst the majority of PBC patients who develop portal hypertension do so in relation 
to cirrhosis, approximately 5-10% of PBC-related gastro-oesophageal varices (GOV) 
manifest in early-stage liver disease secondary to pre-sinusoidal resistance (69, 72, 
73). This is important to recognise, given that the presence of GOV is associated with 
poor 5- and 10-year survival rates in PBC patients; 63% and 26% respectively, in 
comparison to 91% and 83% in patients without GOV. These unacceptably poor 
outcomes led to development of the Newcastle Varices Prediction Score (NVPS), 
which incorporates serum albumin, ALP, platelet count and spleen size, to accurately 
predict the presence of GOV across all disease stages (area under the receiver 
operator characteristic curve [AUROC]: 0.9) (73). Notwithstanding the depth to 
which the NVPS is validated, there may be a pre-selection bias to the model as all 
patients in the original study were recruited only after an endoscopy referral was 
made. Moreover the study was not powered to discriminate effects of ‘clinically 
significant’ varices harbouring risk of haemorrhage, and the independent/additive 
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predictive value of the NVSP-score to conventional biochemical response criteria is 
uncertain. 
 
Hepatic decompensation 
Although UDCA has been shown to improve survival, contemporary studies report a 
cumulative 10-year incidence of developing cirrhosis of 40% (74). Transition from 
compensated to decompensated liver cirrhosis is infrequent (incidence rate [IR] 9.7-
per-1,000 patient years] although imparts a significant mortality risk (time-dependent 
hazard ratio [HR]: 21.5 (75)). In a retrospective study of 3,224 PB  patients, the first 
observed decompensation event was most often ascites (63%); with variceal bleeding 
(23%), hepatic encephalopathy (8%) or a combination of (6%) being less 
prevalent. However the incidence of decompensation events has evolved significantly 
over time, with a 10-year cumulative complication rate of 13.5% for patients studied 
prior to 1990, 9.3% for between 1990 and 2000, and 5.8% for those included after the 
year 2000 (75).  
 
Transplant-free survival differs significantly with respect to type of decompensation 
event (median survival after occurrence of variceal bleeding, encephalopathy, ascites 
or combination of the above: 4.0 years, 3.2 years, 1.6 years, and 0.6 years, 
respectively), likely reflecting progress in the modern management of variceal 
bleeding versus the lack of effective therapy in managing diuretic refractory ascites. 
Risk stratification via the GLOBE score, or an elevated APRI >0.54 after 12 months 
of UDCA therapy, is predictive for future hepatic decompensation events in PBC 
specifically (32, 52, 75), underscoring the prognostic importance of UDCA therapy 
from point of diagnosis. 
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Patients with both an APRI >0.54 and biochemical non-response had a higher 10-year 
complication risk of 37% compared to those patients with an APRI ≤0.54 who met 
biochemical response criteria (3%) (75). Similarly in a prospective study involving 
262 PBC patients with a median follow up of 6.3 years, Shi et al also illustrated that 
incomplete or non-response was a significant risk factor for hepatic decompensation 
[HR 4.275 (95% CI 2.423-7.541)] (76).   
 
Hepatocellular carcinoma 
The overall incidence of hepatocellular carcinoma (HCC) is perceived to be lower for 
PBC patients compared to other chronic liver diseases (77), estimated at 3.4-cases per 
1,000 patient years (n=4.565) (33). Although rare, the development of HCC is a 
critical event in the patient journey, being associated with significantly poorer 
transplant-free and overall survival (HR 22.61) (33).  
 
The latest guidelines from EASL recommend that all cirrhotic patients with PBC 
should be subjected to cancer surveillance (7). This strategy has significant limitations 
given that the incidence of HCC in PBC appears greatest in men who fail to attain 
biochemical response irrespective of underlying liver disease stage (33, 78). This 
contrasts to women with evidence of advanced disease yet who respond to UDCA 
treatment and actually fall into a lower risk group wherein surveillance may not be 
cost effective (33). Indeed, biochemical response status is able to sub-stratify pre-
existing at risk populations, independent and additive to disease stage, having clear 
connotations with regard to HCC surveillance paradigms (Figure 4). Of interest, a 
retrospective study by Cheung et al (n=144) identified that an APRI-r1 >0.54 is also 
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predictive, and together with UDCA response may be applied to refine HCC 
stratification a step further (79).  
 
Complications secondary to chronic cholestasis 
The reduced bile acid secretion as a consequence of prolonged cholestasis may result 
in a degree of lipid malabsorption, although profound vitamin deficiency is rare. 
Milder degrees of hypovitaminosis may however be detected in patients with 
prolonged jaundice, and early studies estimate a prevalence of approximately 30% in 
PBC patients (80). Elevated serum lipid levels are also evident in up to 80% of 
patients with PBC, yet rarely of clinical consequence. The pattern of hyperlipidaemia 
varies depending on stage of disease and paradoxically anti-atherogenic (7). Therefore 
patients are not treated routinely for PBC associated hyperlipidaemia, except for those 
with concomitant vascular risk factors. 
 
By contrast, metabolic bone disease is observed in 20-40% of patients, and 
consequent fracture risk directly associated with low bone mass and indirectly to the 
duration (but not severity) of underlying liver disease (81, 82). The Barcelona group 
have identified that those with a bone mineral density (BMD) T-score lower than −1.5 
carry greatest risk of fragility fractures; thus represent a group for which early 
bisphosphonate therapy is indicated (81). Notably, UDCA has been shown to 
attenuate hyperbilirubinaemia-induced osteoblast apoptosis in vitro although clinical 
correlates are yet to be substantiated (83). 
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Phenotypic heterogeneity and impact on disease progression 
Symptomatic presentations 
Approximately 60% of patients with PBC are asymptomatic at time of diagnosis, 
however as little as 5% remain symptom-free over time (1) (Table 2). It is apparent 
that presenting age and gender are also influential, with young women – a group who 
fail UDCA therapy more commonly – having the greatest symptom burden and 
elevated fatigue scores on quantitative testing (20). Pruritus and fatigue represent the 
archetypal symptoms in chronic cholestasis, and associated with significantly 
impaired quality of life for patients (84). Although non-specific and unrelated to liver 
disease severity, prognostic importance of fatigue is suggested by the Newcastle 
group, who in a prospectively evaluated PBC cohort (n=136) found that fatigued 
patients experienced significantly shorter transplant-free and overall survival (56% 
and 60%, respectively) relative to non-fatigued disease-matched controls (74% and 
77%, respectively; p<0.0001) after 9 years of follow-up (85). The effect appears 
independent of UDCA treatment, although it remains unclear whether symptomatic 
presentations impart additional discriminatory value to biochemical response criteria. 
Consensus biological explanation for fatigue is also lacking, and current data points 
toward both peripheral and central mechanisms (85, 86). An in depth discussion 
regarding mechanisms, impact and management of symptoms in PBC is provided 
elsewhere in this issue (87). 
 
Presenting age and patient sex 
Although PBC is widely considered a disease of middle age, approximately 25% of 
patients are aged 49 years or less at diagnosis. Moreover, an inverse correlation of 
patient age and likelihood of meeting biochemical response was identified in the 
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landmark study by the UK-PBC study group (20). Indeed, biochemical response rates 
(Paris-I) in women exceed 75% for those diagnosed above the age of 50, relative to 
<50% in those aged 40 and below. These results echo those of an earlier, single-centre 
study wherein younger age (<55 years) was associated with an elevated standardised 
mortality ratio (SMR; 7.4) even when adjusted for liver-related death (SMR: 218) 
(88). Younger women more often fail to meet response due to transaminase criteria, 
which may infer a more inflammatory phenotype of disease given that the grade of 
interface hepatitis adversely influences clinical outcome (14, 21, 54). The critical 
influence of presenting age in female patients may allow timely identification of at-
risk patients, prior to assessment of 1-year biochemical response. Because of a 
relatively poor predicted survival it has been proposed that young women become 
eligible for clinical trial entry from the point of PBC diagnosis (89). However, the 
converse also holds true, in that half of all women presenting below the age of 50 will 
indeed attain biochemical response on UDCA therefore inappropriately selected for 
additional therapies should decisions be made from the outset.  
 
Given that up to a quarter of the female PBC population may present at childbearing 
age, it is expected that some may wish to conceive. From a patient perspective, 
pruritus and its treatment are of practical concern, necessitating symptom specific 
therapy in over two-thirds of affected cases (90). An observational cohort study from 
Toronto found that >70% of women with PBC sustain normal liver biochemistry 
values throughout the gestational period, including those for whom disease is deemed 
‘active’ prior to conception. Intra-partum biochemical flares occurred in a minority, 
and serious or adverse maternal consequences were rare. However, in support of an 
autoimmune aetiology, 72% of women develop flares in biochemical disease activity 
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post-partum, irrespective of pre-conception disease behaviour. Post-partum 
biochemical flares most often represented a transient anicteric cholestatic hepatitis 
with an isolated elevation in serum ALP that settled in the first post-partum year (on 
UDCA therapy), with disease progression being a rare occurrence. 
 
A further key finding from the UK-PBC consortium relates to the influence of patient 
sex and response to UDCA; wherein men exhibited a lower propensity toward 
biochemical response than women (63% vs. 76% in women; p<0.001) (20). These 
differences may relate to a more advanced disease stage at diagnosis; and in another 
large well-characterised PBC cohort, event-rates were no longer different between 
men and women when stratified according to disease severity (91). Such observations 
are also likely to explain (in part) the elevated HCC-risk found in male PBC patients 
(74). 
 
Immunoserological variants  
Anti-mitochondrial antibodies are the hallmark of PBC, and whilst detectable in 
>80% of PBC patients AMA positivity holds no prognostic value (22, 23). Although 
diagnostic of PBC in the presence of biochemical cholestasis, AMA positivity may 
also be detectable in 0.5-1% of the general population (92-95).  
 
The true frequency, characteristics and clinical outcomes of individuals with no 
clinical or biochemical evidence of PBC, yet who remain AMA positive, are largely 
unknown. Perhaps the most robust data series in this regard stems from a prospective 
French national study of 229 AMA-positive individuals (78% women; median age 58 
years) wherein the subsequent 5-year incidence rate of PBC was only 16% (96).  
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However, 5-year mortality was 75%, compared to vs. 90% in an age- and sex-
matched control population (p<0.05), despite the fact that no patient actually died 
secondary to PBC. 
 
Up to 50% of patients with ‘definite’ PBC also test positive for disease-specific anti-
nuclear antibodies (ANA), the commonest staining patterns being peri-nuclear/rim-
like membranous (anti-gp210) and multi-nuclear dot (anti-Sp100). AMA reactivity 
holds no prognostic value, and clinical outcomes for AMA-negative patients are no 
different to serologically positive counterparts with PBC. By contrast, anti-gp210 
positivity (present in ~30% of all PBC patients) predicts more aggressive disease, and 
in one study conferred a 6-fold increased risk of progression to liver 
failure/transplantation (97). Moreover, retrospective evaluation of a large PBC cohort 
from China found that the 5-year adverse outcome-free survival of anti-gp210- 
patients was 70%, vs. 85% for anti-gp210-positive patients, respectively (p=0.005). 
Although neither independent nor additive to the predictive power of biochemical 
response, anti-gp210 may assist in the earlier, prospective identification of high-risk 
patients (98).  
 
Another notable ANA-staining pattern in PBC is anti-centromere (ACA), which 
although less-specific, poses a risk factor for developing portal hypertension (17.5 % 
vs. 3.8%; ACA-positive vs. ACA-negative; odds’ ratio [OR] 4.2) (97). Anti-
centromere antibodies are more frequently found in autoimmune connective tissue 
disease, particularly limited systemic scleroderma. Indeed, >60% of patients with 
PBC develop extra-hepatic autoimmune conditions however an impact on overall 
outcome is not readily perceptible (99). 
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Overlap syndromes and crossover presentations 
Primary biliary cholangitis and autoimmune hepatitis (AIH) are both typified 
pathologically by a varying degree of immune-mediated liver injury, with broadly 
similar mechanistic themes (100). The imprecision of such processes, coupled with 
our incomplete understanding of disease aetiology, means that certain common 
features be they biochemical, serological or histological are often observed across the 
spectrum of autoimmune liver disease (101).  
 
The term overlap ‘syndrome’ or crossover presentation is applied to describe ill- 
defined circumstances wherein, either concurrently or sequentially; there exists 
coexistence of AIH as well as clear features of PBC. However, the challenge remains 
that AIH does not have an absolute diagnostic test, rather diagnosed based on the 
presence and relative absence of various markers of clinical, biochemical, serological, 
and histological disease. In light of these clinical challenges the International 
Autoimmune Hepatitis Group (IAIHG) devised a series of weighted criteria with the 
principled intent of standardising parameters, and quantifying the strength of each, in 
order to ensure homogeneity of AIH patient populations in clinical trials. 
Unfortunately over time, the IAIHG scoring system is increasingly applied as a 
diagnostic test (a purpose for which it was never designed), implying that 
manifestations of AIH are somehow unique and can be confined to disease-specific 
borders. Manifestations that are also common to PBC, for instance interface hepatitis, 
presence of autoantibodies and elevated serum immunoglobulin levels, weaken the 
legitimacy of individual diagnoses, and have led to creation of a separate 
classification system for patients, the ‘overlap syndromes.’ In reality, however, so-
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called overlap ‘features’ are frequently shared across the spectrum of autoimmune 
liver diseases, with some clearly being less categorical and objective than others. 
Overlap syndromes or crossover presentations are thus likely to represent, rather than 
a distinct process, the inherent distribution of clinical features across patient 
populations – the more extreme in distribution the more distinct overlap appears.  
 
The incidence and prevalence of AIH overlap features in PBC are therefore hard to 
ascertain because of publication bias, arbitrary and imprecise definitions contained 
within the same overlap designation, and challenges in case definitions (serological 
overlap is arguably not of the same significance as histological overlap), and 
limitations to test interpretation (e.g. anti-nuclear antibodies must be interpreted in the 
context of their immunofluorescence staining pattern, rather than their presence and 
titre). With these caveats in mind, the most readily identified presentation of overlap 
is the simultaneous presence of both diseases, although less commonly the onset of 
AIH and PBC is temporally dissociated, usually with PBC presenting first, having a 
variable interval of 6 months to 13 years before the onset of AIH (102). 
Approximately 10% of patients with all the features of AIH may also be persistently 
AMA positive, which in itself is not synonymous with a distinct syndrome.  
 
In a cohort study of AMA-positive patients with AIH (n=15) (103), those treated 
conventionally with steroids did not show any clinical or histological evidence of 
PBC despite continued detection of AMA over 27-years. Nevertheless, the same 
centre later published a case series of three AIH patients in whom a formal change to 
PBC diagnosis was made between 4 and 15 years following the original AIH 
presentation (104). By contrast, AMA-positive PBC with a degree of parenchymal 
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inflammation akin to that observed in AIH is well-recognised, usually in the form of 
interface or lobular hepatitis. In rare circumstances, this may be more pronounced 
than the cholestatic component with ALT or AST values as >5xULN. In this event 
disease progression is related in part to the severity of interface activity, and 
persistence of serum transaminase activity leading to UDCA non-response (14) (20). 
In a contemporary study by the Parisian group, approximately 55%, 9% and 12% of 
patients exhibited mild, moderate and severe interface hepatitis (19), although the 
precise number in whom (and severity with which) interface hepatitis manifests can 
be difficult to ascertain given the infrequency with which liver biopsy is performed in 
PBC. In any event the seminal trials of UDCA in PBC (n=292) identified moderate-
severe interface hepatitis as conferring a two-fold greater risk of disease progression 
(liver transplantation/death) over a 16-year period (14).  
 
In 2007 the Mayo clinic reported that over an average 5.75-year follow-up, 54% of 
patients with AIH/PBC overlap developed portal hypertensive disease vs. 28% with 
AIH alone; p<0.01), with features of hepatic decompensation and progression to liver 
transplantation/death also being more common (38% vs. 19%; p<0.05) (105). 
Conversely, when Joshi et al. evaluated 16 patients with PBC and overlapping 
features of AIH, the median change in serum biochemistry and immunoglobulin 
values was similar to a cohort with a more classical PBC phenotype after 2 years 
of UDCA alone, with very little change in hepatic lobular inflammatory activity 
(106). Thus it remains unclear whether the clinical outcome of AIH/PBC overlap is 
different to that of isolated AIH or PBC. A detailed discussion regarding therapeutic 
considerations for overlap presentations is beyond the scope of this review, and will 
be discussed elsewhere in the current issue (68). 
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CONCLUSION 
The full appreciation of the breadth of PBC has evolved as awareness has 
risen, leading to a greater understanding of phenotypic presentations and variation 
therein. International cohort studies have facilitated a much greater understanding of 
the patient experience, with recognition that rates of clinical progression vary 
according to presenting age and sex, immunoserological and histological variants, 
symptomatology, and biochemical response to therapy. Whilst the latter defines ‘at-
risk’ patients most readily, determining the rate of clinical progression prior to 
mandatory completion of 1 year on UDCA therapy is urgently commanded. The 
impact of patient age has been better captured in contemporary PBC risk scores, 
however the additive predictive value of histology and its non-invasive surrogates 
requires further investigation, particularly with regard to decompensation events. 
Moving forward, it is hoped that prospective biobanking with paired long-term 
clinical follow-up data will yield predictive markers from the point of diagnosis 
through interrogation of key pathways underlying non-response to conventional 
therapy, akin to that explored in other autoimmune diseases (107). 
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Table 1:  The incidence of hepatic complications and prognostic implications 
Complication  Incidence and prevalence (% 
patients with PBC) 
  
Correlates and Potential Risk 
Factors  
Prognostic Implications 
Portal hypertension (defined as 
PHG>6.0 mm Hg) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Varices  
 
 
 
 
 
Prevalence: 35% (n= 132 patients) 
(69) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incidence at presentation: 9% (72) 
 
Incidence over time (UDCA 
untreated): 31% over 7 years (108) 
 
Overall prevalence (UDCA treated): 
8%-19% (40, 109, 110)  
 
• Elevated Mayo risk 
score (PHG correlates 
significantly with the 
Mayo risk score (r2= 
0.262 P<0.001 (69) 
 
• Advancing liver 
histological stage 
(rs=0.414 P<0.001) (69) 
 
• 12.3% of non-cirrhotic 
patients may have an 
elevated PHG (69, 112-
114) 
 
 
 
 
 
• Male sex. One 
retrospective study (n= 
325) found among 
patients with early 
histological disease, EVs 
were more likely to be 
present in males (111) 
 
• Severity of the PHG is 
associated with shorter 
transplant free survival. 
Percentage probability of 
transplant free survival at 15- 
years; 80% vs 60% vs 30% if 
PHG <= 6, 6-12, >12 mmHg 
respectively P<0.0003 (69) 
 
• Changes in PHG 24-months 
post-UDCA treatment may 
identify responders with 
survival akin to that of a control 
population. Decreased or stable 
PHG predictive of better 
survival (HR 4.64) (69) 
 
 
 
• Presence of GOV associated 
with reduced 5- (63% vs 91%) 
and 10- year (26% vs 83%) 
survival vs patients without 
GOV (73) 
 
• 50% of patients will have a 
bleed event 
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Can manifest in 5-10% patients with 
early stage, pre-cirrhotic PBC (72, 
73, 111) 
 
• Low albumin < 4 g/dl 
(OR 6.02) (115) 
 
•  Thrombocytopenia 
<140 x109 cells/L (OR 
7.6) (110) 
 
• NVPS (incorporates 
serum albumin, ALP, 
platelet count and spleen 
size) accurately predicts 
presence of GOV across 
all disease stages 
(AUROC: 0.9) (73)  
 
• Elevated bilirubin ≥ 1.2 
mg/dl (HR 5.4) (111, 
115) 
 
•  Mayo risk score ≥ 4.5 
(OR 10.6) (110) 
 
•  Advanced histological 
stage (stage III-IV) (69% 
of patients) (108) 
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Hepatic decompensation 
 
 
 
 
 
 
 
 
  
 
 
Overall incidence: 0.97% (75)  
 
 
Among patients who present with 
hepatic decompensation; ascites is 
the most frequent first event (63%) 
vs variceal bleeding (23%) vs 
hepatic encephalopathy (8%) vs 
combination of hepatic 
complications (6%) (75) 
 
• Biochemical non-
response 12-months post 
UDCA therapy (10- year 
cumulative incidence of 
first complication in 
biochemical non-
responders (32.4%) vs 
responders (6.2%)) (75) 
 
• APRI > 0.54 (10-year 
complication rate if 
APRI > 0.54 (24.3%) vs 
APRI ≤ 0.54 (3.8%)) 
(52, 70, 75)  
 
• Advanced liver disease 
(biochemical and 
histological) 
 
- Biochemical: 
abnormal serum 
albumin and/or 
bilirubin (HR 4.34) 
(75) 
 
- Histological: 
advanced Scheuer 
classification (HR 
1.77) (76, 116)  
 
• Occurrence associated with 
reduced 10-year survival rates 
(10.4% vs 85.3%) vs patients 
without complications (75) 
 
• Median survival after: 
 
             Variceal bleeding- 4.0 years 
Encephalopathy-3.2 years 
Ascites- 1.6 years  
Combination of the above- 0.6  
years (75) 
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Hepatocellular carcinoma (HCC) 0.34% (33)  • Male sex (HR 2.91) (33)  
 
- Incidence in men vs 
women, 6.7 vs 2.6 
cases per 1000 
patient-years 
respectively (33) 
 
• Advancing age at PBC 
diagnosis (per 10-year 
increase) (HR 1.21) (33, 
117, 118) 
 
• Advanced biochemical 
(HR 2.72) (33) and 
histological disease (OR 
5.80) (117-121).  
 
• Inadequate biochemical 
response 12-months post 
UDCA therapy (HR 
4.52) (33). An APRI -
r1> 0.54 (HR 3.94) is 
predictive of HCC 
development (79)  
 
•  Significantly poorer transplant-
free and overall survival in 
patients with HCC (HR 22.61) 
(33)  
 
 
ALP- Alkaline phosphatase; AST- Aspartate transaminase; APRI- AST to platelet ratio index; APRI-r1- APRI at 1 year after treatment; EV- 
Esophageal varices; GOV- Gastrooesophageal varices; NVPS- Newcastle varices prediction score; PHG- Porto-hepatic gradient; UDCA-
ursodeoxycholic acid  
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Table 2: Variant presentations in PBC and impact on disease progression 
Phenotypic variants (% patient 
population) 
Impact on disease progression 
Symptomatic presentation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Young presenting age 
(25%) 
 
 
 
Male sex 
(5-10%) 
 
 
 
 
 
 
 
 
 
 
 
 
• 60% asymptomatic at presentation; 
less than 5% remain symptom free 
over time (1) 
 
• Fatigue and pruritus most common 
symptoms (non-specific); unrelated 
to disease severity 
 
In one prospective study (n=136 
patients) fatigued patients 
experienced significantly shorter 
transplant free and overall survival 
(56% and 60% respectively) relative 
to non-fatigued disease-matched 
controls (74% and 77% respectively, 
P<0.0001) (85).  
 
In a second study, fatigue was 
associated with an increased risk of 
liver transplantation or liver related 
death (HR 9.6) (122) 
 
 
• Biochemical response rate is less 
than 50% in women aged ≤ 40 years 
(20)  
 
 
• Older age at presentation relative to 
women (median 60 vs. 55 years; P< 
0.001) (20)  
 
• Higher frequency of biochemical 
non- response (63% vs 76%; P < 
0.001) (91) . Possibly due to more 
advanced disease at diagnosis (20) 
 
• Increased HCC risk in biochemical 
non-responders and cirrhotics (33) 
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Immunoserological variants (% patient 
population) 
Impact on disease progression 
AMA negative  
(5-10% of all patients) 
 
 
ANA positive 
(30-50% of all patients) 
 
 
 
 
 
 
 
 
 
 
 
 
ACA positive 
• Clinical course same as AMA-
positive PBC  
 
 
• PBC specific ANA (anti-gp210 and 
anti-Sp100) can be present 
concurrently with AMA 
 
• Testing for ANA may be useful in 
diagnosing PBC in AMA negative 
patients 
 
• Anti-gp210 positivity associated with 
aggressive disease; six-fold risk of 
progression to liver failure/transplant 
(97)  
 
 
• Associated with significant portal 
hypertension (17.5% vs 3.8%; ACA-
positive vs ACA-negative 
respectively) (97) 
 
Histological variants (% patient 
population) 
Impact on disease progression 
Classical/typical PBC 
 
 
 
 
 
 
 
Premature ductopenic variant (16) 
(5-10%) 
 
 
 
 
 
 
 
 
 
 
Interface hepatitis (moderate-severe) 
• Slow and progressive decline in 
small bile ducts over time; parallel 
increase in fibrosis 
 
• Biliary cirrhosis over 10-20 years 
without UDCA treatment  
 
 
• Characterised by rapid onset 
ductopenia in the absence of 
significant fibrosis or cirrhosis; 
Severe cholestatic jaundice  
 
• Unresponsive to UDCA therapy 
 
• Rapid progression towards cirrhosis 
in less than 5 years requiring liver 
transplantation  
 
 
• Positive correlation with serum 
AST/ALT 
 
• Moderate-severe activity 
independently predictive of 
biochemical non-response, 
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histological stage progression, 
progression to transplantation and 
death (14, 21, 25)  
- Two fold risk of disease 
progression (liver 
transplantation/death) (14)  
 
Biochemical non-responders  • GLOBE score > 0.30 associated with 
reduced survival compared with 
matched general population (HR 5.51 
P< 0.0001) with 5-, 10- and 15- year 
transplant free survival rates of 
79.7%, 57.4% and 42.5% 
respectively (32) 
 
• Increased risk of hepatic 
decompensation events and HCC 
(HR 4.52) (33, 75) 
 
ACA- Anti-centromere antibodies; AMA- Anti-mitochondrial antibodies; ANA- Anti-
nuclear antibodies; ALT- Alanine aminotransferase   AST- Aspartate transaminase; 
HCC- Hepatocellular carcinoma; UDCA- Ursodeoxycholic acid  
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Figure 1: Evolution of biochemical response criteria in PBC 
Several biochemical response criteria are proposed in PBC [A] successful attainment 
at 12 -24 months post UDCA therapy, or following diagnosis for non-treated patients, 
is associated with transplant-free survival akin to that of an age- and sex-matched 
control population. Approximately 2/3rds of the PBC population overall meet 
conventional biochemical response criteria, and [B] attempts have been made to 
validate earlier in the course of therapy in one study (3- and 6- vs 12-months) 
Application of the APRI score at 12 months (APRI-r1) to all pre-existing criteria has 
been shown to improve predictive performance, and [C] furthered the development of 
continuous scoring systems which incorporate both measures of treatment response 
and surrogate markers of disease severity.  
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Figure 2: Impact of UDCA on disease progression 
Several studies have illustrated that UDCA is not only effective at improving liver 
biochemistry but delaying histological progression to cirrhosis, reducing hepatic 
decompensation rates and significantly improving 5-, 10-, and 15- year liver 
transplant free survival in patients with PBC. Absence of biochemical response to 
UDCA has significant prognostic implication including reduced liver transplant free 
survival and higher hepatocellular carcinoma risk. Biochemical response status can be 
used to stratify at-risk patients either independently or additively to disease stage. 
Continuous risk scores such as the UK-PBC score and GLOBE score, which 
incorporate surrogate markers of response to UDCA therapy, have been shown to 
outperform conventional risk models in accurately predicting risk of liver 
transplantation or liver- related death.  
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Figure 3: The PBC drug pipeline in 2018 
Treatment of PBC has advanced over recent years and continues to evolve. Increased 
understanding into genetic risks and biological pathways have led to therapies aimed 
at modulating bile acid physiology and targeting immune responses. UDCA remains 
the standard of care in PBC. However a proportion of patients respond sub-optimally 
to UDCA therefore at risk of hepatic complications and liver transplantation. OCA, a 
farnesoid X receptor agonist, has been licensed as second line therapy in patients with 
inadequate/non-response to UDCA. Other non-licensed drugs showing ongoing 
promise in phase 2/3 clinical trials in PBC include PPAR agnoists (benzafibrate and 
seladelapar) and inhibitors of ileal bile acid transport (GSK 2330672 aimed at treating 
pruritus).  
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Figure 4: Incidence of hepatocellular carcinoma and thresholds for 
  surveillance in at risk groups 
The overall annualised incidence of HCC cases is estimated at 3.4 for every 1000 
patient-years according to the Global PBC Study Group, although varies greatly 
depending upon patient sex, disease stage and biochemical response status. Male 
patients who are non-responders have the highest incidence of HCC irrespective of 
disease stage, whereas by contrast, women who respond to UDCA despite advanced 
disease have a much lower incidence that falls below the threshold in which 
surveillance is recommended by EASL and AASLD (vertical dotted line). Indeed, 
biochemical response status may sub-stratify pre-existing at risk populations, 
independent and additive to disease stage, having significant implications with regard 
to HCC surveillance paradigms.  
PRACTICE POINTS  
 
 
• Rates of disease progression are variable across the PBC population, being 
impacted by heterogeneous phenotypic, histological and immunoserological 
presentations. 
 
• Transplant-free survival is improved for patients under ursodeoxycholic acid 
treatment, with outcome benefit most evident in patients meeting biochemical 
response criteria. 
 
• The GLOBE and UK-PBC scores provide objective quantification measures 
that accurately predict transplant-free survival at specific time-points. 
 
• Hepatic decompensation events are rare (<1% per year) but confer a 
heightened transplant/mortality risk >20-fold.  
 
• HCC risk is heightened risk for men, in addition to patients failing to meet 
biochemical response criteria; whereas the incidence in biochemical 
responders is low, even in the presence of advanced liver disease. 
 
 
RESEARCH AGENDA 
 
• The additive predictive value of histology and its non-invasive surrogates to 
contemporary PBC risk scores requires further investigation. 
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• Prospective bio-banking with paired long-term clinical follow-up data may be 
useful in yielding predictive markers from the point of diagnosis. 
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Barcelona ALP 1 x ULN or decreased by  40% At 1 year
Paris-I ALP 3 x ULN and AST 2 x ULN and bilirubin <1 mg/dL At 1 year
Rotterdam Normalisation of abnormal bilirubin and/or albumin At 1 year
Toronto ALP <1.67 x ULN At 2 years
Paris II ALP 1.5 x ULN and AST 1.5 x ULN and bilirubin <1 mg/dL At 1 year
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APRI-r1 Biochemical response (Barcelona, Paris I/II, or Toronto) and APRI ≤0.54 1 year
Rotterdam Normalisation of abnormal bilirubin and/or albumin "#!$!%&'(!
GLOBE Prognostic index comprising age, and bilirubin, ALP, albumin, and platelet count 1 year
UK-PBC Prognostic index comprising albuminplatelet count, bilirubin, ALT or AST, and ALP 1 year
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UDCA treatment overall
   UDCA treated vs. non-treated 
5y.   LT-free survival 98%   79%
10y. LT-free survival 78%   59%
15y. LT-free survival 66%   32%
 UDCA non-response vs. response 
LT-free survival:   HR 6.72; p<0.001 
HCC:     HR 4.52; p<0.001   
 Prognostic modelling of UDCA-treated patients 
GLOBE score (LT / overall survival):  81% accuracy 
UK-PBC score (LT / liver-related death): 91 - 96% accuracy 
Stratiﬁed risk through theraeputic response
Accurate prediction of clinical events
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